Sarepta Therapeutics Inc (NASDAQ:SRPT) saw unusually large options trading on Friday. Investors bought 22,555 put options on the stock. This represents an increase of 2,651% compared to the average daily volume of 820 put options.

In other Sarepta Therapeutics news, SVP Shamim Ruff sold 10,000 shares of the company’s stock in a transaction dated Monday, November 6th. The stock was sold at an average price of $55.00, for a total transaction of $550,000.00. Following the completion of the sale, the senior vice president now directly owns 37,045 shares in the company, valued at $2,037,475. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Douglas S. Ingram purchased 38,138 shares of the company’s stock in a transaction on Wednesday, November 8th. The shares were purchased at an average price of $52.44 per share, with a total value of $1,999,956.72. Following the completion of the purchase, the chief executive officer now directly owns 420,196 shares of the company’s stock, valued at $22,035,078.24. The disclosure for this purchase can be found here. Corporate insiders own 9.60% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the stock. Ameritas Investment Partners Inc. boosted its holdings in Sarepta Therapeutics by 6.3% in the second quarter. Ameritas Investment Partners Inc. now owns 4,561 shares of the biotechnology company’s stock valued at $154,000 after purchasing an additional 271 shares during the last quarter. Cubist Systematic Strategies LLC boosted its holdings in Sarepta Therapeutics by 116.4% in the second quarter. Cubist Systematic Strategies LLC now owns 4,600 shares of the biotechnology company’s stock valued at $155,000 after purchasing an additional 2,474 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. boosted its holdings in Sarepta Therapeutics by 140.9% in the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,262 shares of the biotechnology company’s stock valued at $193,000 after purchasing an additional 2,493 shares during the last quarter. Fox Run Management L.L.C. purchased a new position in Sarepta Therapeutics in the third quarter valued at about $204,000. Finally, Bayesian Capital Management LP purchased a new position in Sarepta Therapeutics in the second quarter valued at about $206,000. 82.02% of the stock is owned by hedge funds and other institutional investors.

A number of equities research analysts have recently issued reports on SRPT shares. William Blair reiterated an “outperform” rating on shares of Sarepta Therapeutics in a research note on Monday, October 2nd. Zacks Investment Research lowered Sarepta Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, January 5th. Robert W. Baird reiterated an “outperform” rating and issued a $101.00 target price on shares of Sarepta Therapeutics in a research note on Monday, October 2nd. UBS Group reiterated an “outperform” rating and issued a $56.51 target price (down previously from $76.00) on shares of Sarepta Therapeutics in a research note on Wednesday, December 27th. Finally, BidaskClub lowered Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, December 19th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and eighteen have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $63.88.

Sarepta Therapeutics (SRPT) opened at $60.15 on Wednesday. The company has a market capitalization of $3,890.00, a PE ratio of -29.49 and a beta of 1.37. Sarepta Therapeutics has a 1-year low of $26.26 and a 1-year high of $62.85. The company has a quick ratio of 9.52, a current ratio of 10.44 and a debt-to-equity ratio of 0.04.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.66. The firm had revenue of $45.95 million during the quarter, compared to the consensus estimate of $41.29 million. Sarepta Therapeutics had a negative return on equity of 51.72% and a negative net margin of 112.08%. During the same quarter in the prior year, the business posted ($0.95) earnings per share. equities analysts forecast that Sarepta Therapeutics will post -3.07 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Sarepta Therapeutics Sees Unusually High Options Volume (SRPT)” was first reported by Watch List News and is the property of of Watch List News. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The correct version of this news story can be accessed at https://www.watchlistnews.com/sarepta-therapeutics-sees-unusually-high-options-volume-srpt/1809975.html.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.